EP Biocomposites has scheduled its seventh annual general meeting for Monday, September 28, 2026. The meeting will be held at the Bicholim Industrial Estate Hall in Goa at 4:00 pm.

Shareholders will consider ordinary business items, including the adoption of audited financial statements for the fiscal year ended March 31, 2026. The board also seeks approval for the re-appointment of Mr. Rajkumar Kamat as managing director.

Key Agenda Items

The notice outlines two primary resolutions for shareholder approval:

• Adoption of the audited financial statements and reports of the Board of Directors and Auditors for FY26.
• Re-appointment of Mr. Rajkumar Kamat (DIN: 01157652), who retires by rotation and offers himself for re-election.

Voting and Logistics

The company is facilitating remote e-voting through Bigshare Services Private Limited. The voting window opens on Thursday, September 24, 2026, at 10:00 am and closes on Sunday, September 27, 2026, at 5:00 pm. Members holding shares as of the cut-off date, Wednesday, September 23, 2026, are eligible to vote.

CS Amogh Diwan has been appointed as the scrutinizer to oversee the voting process. Results will be declared immediately after the meeting and posted on the company website.

EP Biocomposites Limited reported a 41.5% increase in net profit to ₹145.83 lakh for the financial year ended March 31, 2026, driven by a 13.6% rise in revenue and improved operational efficiency. Revenue from operations grew to ₹1,363.98 lakh from ₹1,200.62 lakh in the previous year. The board of directors approved the audited financial statements for the year at a meeting held on May 26, 2026.

The company’s EBITDA for FY26 stood at ₹237.83 lakh, a 26.23% increase from ₹188.41 lakh in FY25, with margins expanding to 17.44%. Profit before tax improved to ₹193.73 lakh from ₹141.70 lakh in the same period. Earnings per share (EPS) increased to ₹8.67 from ₹6.13 in the previous year. The statutory auditors carried out the audit of the financial statements, confirming compliance with applicable accounting standards.

Financial Performance

The following table outlines the key financial metrics for EP Biocomposites Limited for the year ended March 31, 2026:

Operational Highlights

Net worth crossed ₹12 crore as of March 31, 2026, reflecting continued financial strengthening. Return on Investment (ROI) stood at 14%, while Return on Capital Employed (ROCE) improved to 16% during FY26. The company successfully utilized IPO proceeds towards capacity expansion, working capital, and business growth initiatives, strengthening the balance sheet through partial debt repayment and improved liquidity.

Balance Sheet Highlights

The company’s balance sheet strengthened with total assets increasing to ₹1,873.14 lakh as of March 31, 2026, compared to ₹1,662.66 lakh a year ago. Shareholders' funds rose to ₹1,205.30 lakh from ₹1,059.48 lakh, supported by reserves and surplus which grew to ₹1,037.15 lakh. Cash and cash equivalents improved significantly to ₹215.35 lakh from ₹161.67 lakh, indicating robust liquidity.